Background Targeted anticancer treatments (TATs) are drugs or other substances that act on a specific target or biological pathway associated with tumour growth and dissemination. These treatments can be used alone or in combination with chemotherapy in first-line, refractory, or relapsed settings.
Purpose To evaluate the use of TAT in adult onco/haematological patients treated in our hospital and to estimate the financial impact of these treatments.
Materials and methods Retrospective study of adult onco/hematological patients treated with TAT from February 2011 to September 2011. Literature was reviewed to define the drugs classified as TAT. Data were obtained from: pharmacy management program, hospital oncology software and outpatient pharmacotherapy history. Variables studied were: TAT, number of patients, chemotherapy protocols (used in combination with chemotherapy or monotherapy), treatment cost.
Results 1788 active patients received chemotherapy during the study period of whom 536 (29.98%) were in treatment with some TAT. The distribution of patients being treated with each drug was the following:
TATs were used in combination with conventional chemotherapy in 268 patients and in 301 patients as monotherapy. Cost of TAT was 6,357,299.55 euros which represented 73.15% of total cost of all chemotherapy treatments (8,690,640.4 euros).
Conclusions Targeted treatment is a widely used cancer treatment option. Most of the financial cost of cancer treatment is related to TATs so these drugs should be selected and used correctly according to hospital protocols.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.